{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T07:25:39Z","timestamp":1788852339535,"version":"build-2803163510"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,5,2]],"date-time":"2017-05-02T00:00:00Z","timestamp":1493683200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s12185-017-2242-0","type":"journal-article","created":{"date-parts":[[2017,5,2]],"date-time":"2017-05-02T08:17:39Z","timestamp":1493713059000},"page":"720-731","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Splicing factor mutations in MDS RARS and MDS\/MPN-RS-T"],"prefix":"10.1007","volume":"105","author":[{"given":"Akihide","family":"Yoshimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Abdel-Wahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,2]]},"reference":[{"issue":"20","key":"2242_CR1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405.","journal-title":"Blood"},{"key":"2242_CR2","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. New York: WHO Press; 2008."},{"issue":"4","key":"2242_CR3","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1046\/j.1365-2141.2000.01940.x","volume":"108","author":"U Germing","year":"2000","unstructured":"Germing U, Gattermann N, Aivado M, Hildebrandt B, Aul C. Two types of acquired idiopathic sideroblastic anaemia (AISA): a time-tested distinction. Br J Haematol. 2000;108(4):724\u20138.","journal-title":"Br J Haematol"},{"issue":"15","key":"2242_CR4","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","volume":"365","author":"E Papaemmanuil","year":"2011","unstructured":"Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011;365(15):1384\u201395.","journal-title":"N Engl J Med"},{"issue":"7367","key":"2242_CR5","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nature10496","volume":"478","author":"K Yoshida","year":"2011","unstructured":"Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367):64\u20139.","journal-title":"Nature"},{"issue":"2","key":"2242_CR6","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/blood-2015-03-633537","volume":"126","author":"L Malcovati","year":"2015","unstructured":"Malcovati L, Karimi M, Papaemmanuil E, Ambaglio I, Jadersten M, Jansson M, et al. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood. 2015;126(2):233\u201341.","journal-title":"Blood"},{"issue":"24","key":"2242_CR7","doi-asserted-by":"crossref","first-page":"6239","DOI":"10.1182\/blood-2011-09-377275","volume":"118","author":"L Malcovati","year":"2011","unstructured":"Malcovati L, Papaemmanuil E, Bowen DT, Boultwood J, Della Porta MG, Pascutto C, et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic\/myeloproliferative neoplasms. Blood. 2011;118(24):6239\u201346.","journal-title":"Blood"},{"issue":"25","key":"2242_CR8","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2013-09-381665","volume":"122","author":"M Cazzola","year":"2013","unstructured":"Cazzola M, Della Porta MG, Malcovati L. The genetic basis of myelodysplasia and its clinical relevance. Blood. 2013;122(25):4021\u201334.","journal-title":"Blood"},{"issue":"27","key":"2242_CR9","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1200\/JCO.2011.40.7379","volume":"30","author":"R Bejar","year":"2012","unstructured":"Bejar R, Stevenson KE, Caughey BA, Abdel-Wahab O, Steensma DP, Galili N, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2012;30(27):3376\u201382.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2242_CR10","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/blood-2011-09-377994","volume":"119","author":"MM Patnaik","year":"2012","unstructured":"Patnaik MM, Lasho TL, Hodnefield JM, Knudson RA, Ketterling RP, Garcia-Manero G, et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood. 2012;119(2):569\u201372.","journal-title":"Blood"},{"issue":"9","key":"2242_CR11","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1038\/leu.2013.120","volume":"27","author":"J Broseus","year":"2013","unstructured":"Broseus J, Alpermann T, Wulfert M, Florensa Brichs L, Jeromin S, Lippert E, et al. Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia. 2013;27(9):1826\u201331.","journal-title":"Leukemia"},{"issue":"2","key":"2242_CR12","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.3324\/haematol.2012.072538","volume":"98","author":"S Jeromin","year":"2013","unstructured":"Jeromin S, Haferlach T, Grossmann V, Alpermann T, Kowarsch A, Haferlach C, et al. High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic\/myeloproliferative neoplasms. Haematologica. 2013;98(2):e15\u20137.","journal-title":"Haematologica"},{"issue":"5","key":"2242_CR13","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/ajh.24332","volume":"91","author":"MM Patnaik","year":"2016","unstructured":"Patnaik MM, Lasho TL, Finke CM, Hanson CA, King RL, Ketterling RP, et al. Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing. Am J Hematol. 2016;91(5):492\u20138.","journal-title":"Am J Hematol"},{"issue":"25","key":"2242_CR14","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391\u2013405.","journal-title":"N Engl J Med"},{"issue":"25","key":"2242_CR15","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379\u201390.","journal-title":"N Engl J Med"},{"issue":"6","key":"2242_CR16","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1038\/leu.2014.49","volume":"28","author":"J Broseus","year":"2014","unstructured":"Broseus J, Lippert E, Harutyunyan AS, Jeromin S, Zipperer E, Florensa L, et al. Low rate of calreticulin mutations in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia. 2014;28(6):1374\u20136.","journal-title":"Leukemia"},{"issue":"7","key":"2242_CR17","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.3324\/haematol.2011.053918","volume":"97","author":"J Broseus","year":"2012","unstructured":"Broseus J, Florensa L, Zipperer E, Schnittger S, Malcovati L, Richebourg S, et al. Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis. Haematologica. 2012;97(7):1036\u201341.","journal-title":"Haematologica"},{"key":"2242_CR18","doi-asserted-by":"crossref","unstructured":"Bottomley SS, Fleming MD. Sideroblastic anemia: diagnosis and management. Hematol Oncol Clin N Am. 2014;28(4):653\u201370 (v).","DOI":"10.1016\/j.hoc.2014.04.008"},{"issue":"6","key":"2242_CR19","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/ped.12217","volume":"55","author":"T Fujiwara","year":"2013","unstructured":"Fujiwara T, Harigae H. Pathophysiology and genetic mutations in congenital sideroblastic anemia. Pediatr Int. 2013;55(6):675\u20139.","journal-title":"Pediatr Int"},{"issue":"2","key":"2242_CR20","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/pbc.22244","volume":"54","author":"AK Bergmann","year":"2010","unstructured":"Bergmann AK, Campagna DR, McLoughlin EM, Agarwal S, Fleming MD, Bottomley SS, et al. Systematic molecular genetic analysis of congenital sideroblastic anemia: evidence for genetic heterogeneity and identification of novel mutations. Pediatr Blood Cancer. 2010;54(2):273\u20138.","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"2242_CR21","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1073\/pnas.89.9.4028","volume":"89","author":"PD Cotter","year":"1992","unstructured":"Cotter PD, Baumann M, Bishop DF. Enzymatic defect in \u201cX-linked\u201d sideroblastic anemia: molecular evidence for erythroid delta-aminolevulinate synthase deficiency. Proc Natl Acad Sci USA. 1992;89(9):4028\u201332.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"2242_CR22","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1182\/blood.V91.3.798","volume":"91","author":"H Harigae","year":"1998","unstructured":"Harigae H, Suwabe N, Weinstock PH, Nagai M, Fujita H, Yamamoto M, et al. Deficient heme and globin synthesis in embryonic stem cells lacking the erythroid-specific delta-aminolevulinate synthase gene. Blood. 1998;91(3):798\u2013805.","journal-title":"Blood"},{"issue":"6","key":"2242_CR23","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/ng.359","volume":"41","author":"DL Guernsey","year":"2009","unstructured":"Guernsey DL, Jiang H, Campagna DR, Evans SC, Ferguson M, Kellogg MD, et al. Mutations in mitochondrial carrier family gene SLC25A38 cause nonsyndromic autosomal recessive congenital sideroblastic anemia. Nat Genet. 2009;41(6):651\u20133.","journal-title":"Nat Genet"},{"issue":"6","key":"2242_CR24","doi-asserted-by":"crossref","first-page":"808","DOI":"10.3324\/haematol.2010.039164","volume":"96","author":"C Kannengiesser","year":"2011","unstructured":"Kannengiesser C, Sanchez M, Sweeney M, Hetet G, Kerr B, Moran E, et al. Missense SLC25A38 variations play an important role in autosomal recessive inherited sideroblastic anemia. Haematologica. 2011;96(6):808\u201313.","journal-title":"Haematologica"},{"issue":"10","key":"2242_CR25","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1172\/JCI76979","volume":"124","author":"YY Yien","year":"2014","unstructured":"Yien YY, Robledo RF, Schultz IJ, Takahashi-Makise N, Gwynn B, Bauer DE, et al. TMEM14C is required for erythroid mitochondrial heme metabolism. J Clin Invest. 2014;124(10):4294\u2013304.","journal-title":"J Clin Invest."},{"issue":"4","key":"2242_CR26","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1136\/jmg.22.4.267","volume":"22","author":"RA Pagon","year":"1985","unstructured":"Pagon RA, Bird TD, Detter JC, Pierce I. Hereditary sideroblastic anaemia and ataxia: an X linked recessive disorder. J Med Genet. 1985;22(4):267\u201373.","journal-title":"J Med Genet"},{"issue":"6","key":"2242_CR27","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.ejpn.2012.02.003","volume":"16","author":"M D\u2019Hooghe","year":"2012","unstructured":"D\u2019Hooghe M, Selleslag D, Mortier G, Van Coster R, Vermeersch P, Billiet J, et al. X-linked sideroblastic anemia and ataxia: a new family with identification of a fourth ABCB7 gene mutation. Eur J Paediatr Neurol. 2012;16(6):730\u20135.","journal-title":"Eur J Paediatr Neurol."},{"issue":"9","key":"2242_CR28","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1182\/blood.V96.9.3256","volume":"96","author":"S Bekri","year":"2000","unstructured":"Bekri S, Kispal G, Lange H, Fitzsimons E, Tolmie J, Lill R, et al. Human ABC7 transporter: gene structure and mutation causing X-linked sideroblastic anemia with ataxia with disruption of cytosolic iron\u2013sulfur protein maturation. Blood. 2000;96(9):3256\u201364.","journal-title":"Blood"},{"issue":"14","key":"2242_CR29","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1093\/emboj\/18.14.3981","volume":"18","author":"G Kispal","year":"1999","unstructured":"Kispal G, Csere P, Prohl C, Lill R. The mitochondrial proteins Atm1p and Nfs1p are essential for biogenesis of cytosolic Fe\/S proteins. EMBO J. 1999;18(14):3981\u20139.","journal-title":"EMBO J"},{"issue":"4","key":"2242_CR30","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1182\/blood-2007-02-072520","volume":"110","author":"C Camaschella","year":"2007","unstructured":"Camaschella C, Campanella A, De Falco L, Boschetto L, Merlini R, Silvestri L, et al. The human counterpart of zebrafish shiraz shows sideroblastic-like microcytic anemia and iron overload. Blood. 2007;110(4):1353\u20138.","journal-title":"Blood"},{"issue":"6","key":"2242_CR31","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1086\/421530","volume":"74","author":"Y Bykhovskaya","year":"2004","unstructured":"Bykhovskaya Y, Casas K, Mengesha E, Inbal A, Fischel-Ghodsian N. Missense mutation in pseudouridine synthase 1 (PUS1) causes mitochondrial myopathy and sideroblastic anemia (MLASA). Am J Hum Genet. 2004;74(6):1303\u20138.","journal-title":"Am J Hum Genet"},{"issue":"1","key":"2242_CR32","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ajhg.2010.06.001","volume":"87","author":"LG Riley","year":"2010","unstructured":"Riley LG, Cooper S, Hickey P, Rudinger-Thirion J, McKenzie M, Compton A, et al. Mutation of the mitochondrial tyrosyl-tRNA synthetase gene, YARS2, causes myopathy, lactic acidosis, and sideroblastic anemia\u2014MLASA syndrome. Am J Hum Genet. 2010;87(1):52\u20139.","journal-title":"Am J Hum Genet"},{"issue":"5","key":"2242_CR33","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1172\/JCI114881","volume":"86","author":"A Rotig","year":"1990","unstructured":"Rotig A, Cormier V, Blanche S, Bonnefont JP, Ledeist F, Romero N, et al. Pearson\u2019s marrow-pancreas syndrome. A multisystem mitochondrial disorder in infancy. J Clin Invest. 1990;86(5):1601\u20138.","journal-title":"J Clin Invest."},{"issue":"15","key":"2242_CR34","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1182\/blood-2016-05-719062","volume":"128","author":"DA Lichtenstein","year":"2016","unstructured":"Lichtenstein DA, Crispin AW, Sendamarai AK, Campagna DR, Schmitz-Abe K, Sousa CM, et al. A recurring mutation in the respiratory complex 1 protein NDUFB11 is responsible for a novel form of X-linked sideroblastic anemia. Blood. 2016;128(15):1913\u20137.","journal-title":"Blood"},{"issue":"25","key":"2242_CR35","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1182\/blood-2015-09-659854","volume":"126","author":"K Schmitz-Abe","year":"2015","unstructured":"Schmitz-Abe K, Ciesielski SJ, Schmidt PJ, Campagna DR, Rahimov F, Schilke BA, et al. Congenital sideroblastic anemia due to mutations in the mitochondrial HSP70 homologue HSPA9. Blood. 2015;126(25):2734\u20138.","journal-title":"Blood"},{"issue":"18","key":"2242_CR36","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1182\/blood-2014-08-591370","volume":"124","author":"PK Chakraborty","year":"2014","unstructured":"Chakraborty PK, Schmitz-Abe K, Kennedy EK, Mamady H, Naas T, Durie D, et al. Mutations in TRNT1 cause congenital sideroblastic anemia with immunodeficiency, fevers, and developmental delay (SIFD). Blood. 2014;124(18):2867\u201371.","journal-title":"Blood"},{"issue":"5","key":"2242_CR37","doi-asserted-by":"crossref","first-page":"e0126555","DOI":"10.1371\/journal.pone.0126555","volume":"10","author":"M Rey del","year":"2015","unstructured":"del Rey M, Benito R, Fontanillo C, Campos-Laborie FJ, Janusz K, Velasco-Hernandez T, et al. Deregulation of genes related to iron and mitochondrial metabolism in refractory anemia with ring sideroblasts. PLoS One. 2015;10(5):e0126555.","journal-title":"PLoS One"},{"issue":"12","key":"2242_CR38","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.15252\/embr.201541116","volume":"16","author":"E Daguenet","year":"2015","unstructured":"Daguenet E, Dujardin G, Valcarcel J. The pathogenicity of splicing defects: mechanistic insights into pre-mRNA processing inform novel therapeutic approaches. EMBO Rep. 2015;16(12):1640\u201355.","journal-title":"EMBO Rep"},{"key":"2242_CR39","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1146\/annurev-biochem-060614-034316","volume":"84","author":"Y Lee","year":"2015","unstructured":"Lee Y, Rio DC. Mechanisms and regulation of alternative pre-mRNA splicing. Annu Rev Biochem. 2015;84:291\u2013323.","journal-title":"Annu Rev Biochem"},{"key":"2242_CR40","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.sbi.2015.12.005","volume":"36","author":"TH Nguyen","year":"2016","unstructured":"Nguyen TH, Galej WP, Fica SM, Lin PC, Newman AJ, Nagai K. CryoEM structures of two spliceosomal complexes: starter and dessert at the spliceosome feast. Curr Opin Struct Biol. 2016;36:48\u201357.","journal-title":"Curr Opin Struct Biol"},{"issue":"1","key":"2242_CR41","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.tibs.2015.11.003","volume":"41","author":"P Papasaikas","year":"2016","unstructured":"Papasaikas P, Valcarcel J. The spliceosome: the ultimate RNA chaperone and sculptor. Trends Biochem Sci. 2016;41(1):33\u201345.","journal-title":"Trends Biochem Sci"},{"issue":"2","key":"2242_CR42","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1158\/1078-0432.CCR-16-0131","volume":"23","author":"A Yoshimi","year":"2017","unstructured":"Yoshimi A, Abdel-Wahab O. Molecular pathways: understanding and targeting mutant spliceosomal proteins. Clin Cancer Res. 2017;23(2):336\u201341.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2242_CR43","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.gene.2016.04.057","volume":"587","author":"M Sahebi","year":"2016","unstructured":"Sahebi M, Hanafi MM, van Wijnen AJ, Azizi P, Abiri R, Ashkani S, et al. Towards understanding pre-mRNA splicing mechanisms and the role of SR proteins. Gene. 2016;587(2):107\u201319.","journal-title":"Gene"},{"issue":"7","key":"2242_CR44","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrc.2016.51","volume":"16","author":"H Dvinge","year":"2016","unstructured":"Dvinge H, Kim E, Abdel-Wahab O, Bradley RK. RNA splicing factors as oncoproteins and tumour suppressors. Nat Rev Cancer. 2016;16(7):413\u201330.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"2242_CR45","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.ccell.2016.08.006","volume":"30","author":"EA Obeng","year":"2016","unstructured":"Obeng EA, Chappell RJ, Seiler M, Chen MC, Campagna DR, Schmidt PJ, et al. Physiologic expression of Sf3b1(K700E) causes impaired erythropoiesis, aberrant splicing, and sensitivity to therapeutic spliceosome modulation. Cancer Cell. 2016;30(3):404\u201317.","journal-title":"Cancer Cell"},{"issue":"3","key":"2242_CR46","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/leu.2016.251","volume":"31","author":"A Mupo","year":"2017","unstructured":"Mupo A, Seiler M, Sathiaseelan V, Pance A, Yang Y, Agrawal AA, Iorio F, Bautista R, Pacharne S, Tzelepis K, Manes N, Wright P, Papaemmanuil E, Kent DG, Campbell PC, Buonamici S, Bolli N, Vassiliou GS. Hemopoietic-specific Sf3b1-K700E knock-in mice display the splicing defect seen in human MDS but develop anemia without ring sideroblasts. Leukemia. 2017;31(3):720\u2013727. doi: 10.1038\/leu.2016.251","journal-title":"Leukemia."},{"issue":"26","key":"2242_CR47","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","volume":"364","author":"R Bejar","year":"2011","unstructured":"Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364(26):2496\u2013506.","journal-title":"N Engl J Med"},{"issue":"7","key":"2242_CR48","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/ng.391","volume":"41","author":"SM Langemeijer","year":"2009","unstructured":"Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M, et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet. 2009;41(7):838\u201342.","journal-title":"Nat Genet"},{"issue":"5","key":"2242_CR49","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.celrep.2015.09.053","volume":"13","author":"RB Darman","year":"2015","unstructured":"Darman RB, Seiler M, Agrawal AA, Lim KH, Peng S, Aird D, et al. Cancer-associated SF3B1 hotspot mutations induce cryptic 3\u2032 splice site selection through use of a different branch point. Cell Rep. 2015;13(5):1033\u201345.","journal-title":"Cell Rep."},{"issue":"3","key":"2242_CR50","doi-asserted-by":"crossref","first-page":"e1004105","DOI":"10.1371\/journal.pcbi.1004105","volume":"11","author":"C DeBoever","year":"2015","unstructured":"DeBoever C, Ghia EM, Shepard PJ, Rassenti L, Barrett CL, Jepsen K, et al. Transcriptome sequencing reveals potential mechanism of cryptic 3\u2032 splice site selection in SF3B1-mutated cancers. PLoS Comput Biol. 2015;11(3):e1004105.","journal-title":"PLoS Comput Biol"},{"key":"2242_CR51","doi-asserted-by":"publisher","unstructured":"Carrocci TJ, Zoerner DM, Paulson JC, Hoskins AA. SF3b1 mutations associated with myelodysplastic syndromes alter the fidelity of branchsite selection in yeast. Nucleic Acids Res. 2017. doi: 10.1093\/nar\/gkw1349","DOI":"10.1093\/nar\/gkw1349"},{"issue":"24","key":"2242_CR52","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1101\/gad.291872.116","volume":"30","author":"Q Tang","year":"2016","unstructured":"Tang Q, Rodriguez-Santiago S, Wang J, Pu J, Yuste A, Gupta V, et al. SF3B1\/Hsh155 HEAT motif mutations affect interaction with the spliceosomal ATPase Prp5, resulting in altered branch site selectivity in pre-mRNA splicing. Genes Dev. 2016;30(24):2710\u201323.","journal-title":"Genes Dev"},{"issue":"2","key":"2242_CR53","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.molcel.2016.08.036","volume":"64","author":"C Cretu","year":"2016","unstructured":"Cretu C, Schmitzova J, Ponce-Salvatierra A, Dybkov O, De Laurentiis EI, Sharma K, et al. Molecular architecture of SF3b and structural consequences of its cancer-related mutations. Mol Cell. 2016;64(2):307\u201319.","journal-title":"Mol Cell"},{"issue":"9","key":"2242_CR54","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1038\/leu.2014.73","volume":"28","author":"M Matsunawa","year":"2014","unstructured":"Matsunawa M, Yamamoto R, Sanada M, Sato-Otsubo A, Shiozawa Y, Yoshida K, et al. Haploinsufficiency of Sf3b1 leads to compromised stem cell function but not to myelodysplasia. Leukemia. 2014;28(9):1844\u201350.","journal-title":"Leukemia"},{"issue":"21","key":"2242_CR55","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1182\/blood-2013-12-544544","volume":"123","author":"C Wang","year":"2014","unstructured":"Wang C, Sashida G, Saraya A, Ishiga R, Koide S, Oshima M, et al. Depletion of Sf3b1 impairs proliferative capacity of hematopoietic stem cells but is not sufficient to induce myelodysplasia. Blood. 2014;123(21):3336\u201343.","journal-title":"Blood"},{"issue":"16","key":"2242_CR56","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1182\/blood-2012-05-430876","volume":"120","author":"V Visconte","year":"2012","unstructured":"Visconte V, Rogers HJ, Singh J, Barnard J, Bupathi M, Traina F, et al. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. Blood. 2012;120(16):3173\u201386.","journal-title":"Blood"},{"key":"2242_CR57","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13045-014-0089-x","volume":"7","author":"V Visconte","year":"2014","unstructured":"Visconte V, Tabarroki A, Zhang L, Parker Y, Hasrouni E, Mahfouz R, et al. Splicing factor 3b subunit 1 (sf3b1) haploinsufficient mice display features of low risk myelodysplastic syndromes with ring sideroblasts. J Hematol Oncol. 2014;7:89.","journal-title":"J Hematol Oncol."},{"issue":"5","key":"2242_CR58","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1101\/gad.1284605","volume":"19","author":"K Isono","year":"2005","unstructured":"Isono K, Mizutani-Koseki Y, Komori T, Schmidt-Zachmann MS, Koseki H. Mammalian polycomb-mediated repression of Hox genes requires the essential spliceosomal protein Sf3b1. Genes Dev. 2005;19(5):536\u201341.","journal-title":"Genes Dev"},{"issue":"8","key":"2242_CR59","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1182\/blood-2006-04-015768","volume":"109","author":"C Pondarre","year":"2007","unstructured":"Pondarre C, Campagna DR, Antiochos B, Sikorski L, Mulhern H, Fleming MD. Abcb7, the gene responsible for X-linked sideroblastic anemia with ataxia, is essential for hematopoiesis. Blood. 2007;109(8):3567\u20139.","journal-title":"Blood"},{"issue":"8","key":"2242_CR60","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1038\/leu.2015.178","volume":"29","author":"H Dolatshad","year":"2015","unstructured":"Dolatshad H, Pellagatti A, Fernandez-Mercado M, Yip BH, Malcovati L, Attwood M, et al. Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells. Leukemia. 2015;29(8):1798.","journal-title":"Leukemia"},{"issue":"1","key":"2242_CR61","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/leu.2014.170","volume":"29","author":"V Visconte","year":"2015","unstructured":"Visconte V, Avishai N, Mahfouz R, Tabarroki A, Cowen J, Sharghi-Moshtaghin R, et al. Distinct iron architecture in SF3B1-mutant myelodysplastic syndrome patients is linked to an SLC25A37 splice variant with a retained intron. Leukemia. 2015;29(1):188\u201395.","journal-title":"Leukemia"},{"issue":"17","key":"2242_CR62","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood-2013-03-492884","volume":"122","author":"L Malcovati","year":"2013","unstructured":"Malcovati L, Hellstrom-Lindberg E, Bowen D, Ades L, Cermak J, Del Canizo C, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013;122(17):2943\u201364.","journal-title":"Blood"},{"key":"2242_CR63","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.leukres.2016.11.008","volume":"52","author":"A Almeida","year":"2017","unstructured":"Almeida A, Fenaux P, List AF, Raza A, Platzbecker U, Santini V. Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS). Leuk Res. 2017;52:50\u20137.","journal-title":"Leuk Res"},{"issue":"6","key":"2242_CR64","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s11899-016-0347-9","volume":"11","author":"A Mies","year":"2016","unstructured":"Mies A, Hermine O, Platzbecker U. Activin receptor II ligand traps and their therapeutic potential in myelodysplastic syndromes with ring sideroblasts. Curr Hematol Malig Rep. 2016;11(6):416\u201324.","journal-title":"Curr Hematol Malig Rep."},{"issue":"4","key":"2242_CR65","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/nm.3512","volume":"20","author":"RN Suragani","year":"2014","unstructured":"Suragani RN, Cadena SM, Cawley SM, Sako D, Mitchell D, Li R, et al. Transforming growth factor-beta superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med. 2014;20(4):408\u201314.","journal-title":"Nat Med"},{"issue":"4","key":"2242_CR66","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.2009.23.8329","volume":"28","author":"P Fenaux","year":"2010","unstructured":"Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing U, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28(4):562\u20139.","journal-title":"J Clin Oncol"},{"issue":"8","key":"2242_CR67","doi-asserted-by":"crossref","first-page":"918","DOI":"10.3324\/haematol.2015.140988","volume":"101","author":"S Thepot","year":"2016","unstructured":"Thepot S, Ben Abdelali R, Chevret S, Renneville A, Beyne-Rauzy O, Prebet T, et al. A randomized phase II trial of azacitidine\u00a0+\/\u2212\u00a0epoetin-beta in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents. Haematologica. 2016;101(8):918\u201325.","journal-title":"Haematologica"},{"issue":"6","key":"2242_CR68","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1182\/blood-2015-04-640128","volume":"127","author":"V Chesnais","year":"2016","unstructured":"Chesnais V, Renneville A, Toma A, Lambert J, Passet M, Dumont F, et al. Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion. Blood. 2016;127(6):749\u201360.","journal-title":"Blood"},{"issue":"10","key":"2242_CR69","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJMoa1310523","volume":"373","author":"A Tefferi","year":"2015","unstructured":"Tefferi A, Lasho TL, Begna KH, Patnaik MM, Zblewski DL, Finke CM, et al. A pilot study of the telomerase inhibitor imetelstat for myelofibrosis. N Engl J Med. 2015;373(10):908\u201319.","journal-title":"N Engl J Med"},{"issue":"9","key":"2242_CR70","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nchembio.2007.16","volume":"3","author":"Y Kotake","year":"2007","unstructured":"Kotake Y, Sagane K, Owa T, Mimori-Kiyosue Y, Shimizu H, Uesugi M, et al. Splicing factor SF3b as a target of the antitumor natural product pladienolide. Nat Chem Biol. 2007;3(9):570\u20135.","journal-title":"Nat Chem Biol"},{"issue":"9","key":"2242_CR71","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/nchembio.2007.18","volume":"3","author":"D Kaida","year":"2007","unstructured":"Kaida D, Motoyoshi H, Tashiro E, Nojima T, Hagiwara M, Ishigami K, et al. Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA. Nat Chem Biol. 2007;3(9):576\u201383.","journal-title":"Nat Chem Biol"},{"issue":"6","key":"2242_CR72","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1021\/cb100356k","volume":"6","author":"L Fan","year":"2011","unstructured":"Fan L, Lagisetti C, Edwards CC, Webb TR, Potter PM. Sudemycins, novel small molecule analogues of FR901464, induce alternative gene splicing. ACS Chem Biol. 2011;6(6):582\u20139.","journal-title":"ACS Chem Biol"},{"issue":"11","key":"2242_CR73","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nrd3823","volume":"11","author":"S Bonnal","year":"2012","unstructured":"Bonnal S, Vigevani L, Valcarcel J. The spliceosome as a target of novel antitumour drugs. Nat Rev Drug Discov. 2012;11(11):847\u201359.","journal-title":"Nat Rev Drug Discov."},{"key":"2242_CR74","doi-asserted-by":"publisher","unstructured":"Effenberger KA, Urabe VK, Jurica MS. Modulating splicing with small molecular inhibitors of the spliceosome. Wiley Interdiscip Rev RNA. 2017;8(2). doi: 10.1002\/wrna.1381","DOI":"10.1002\/wrna.1381"},{"issue":"5","key":"2242_CR75","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1101\/gad.2009411","volume":"25","author":"EG Folco","year":"2011","unstructured":"Folco EG, Coil KE, Reed R. The anti-tumor drug E7107 reveals an essential role for SF3b in remodeling U2 snRNP to expose the branch point-binding region. Genes Dev. 2011;25(5):440\u20134.","journal-title":"Genes Dev"},{"issue":"6","key":"2242_CR76","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/nm.4097","volume":"22","author":"SC Lee","year":"2016","unstructured":"Lee SC, Dvinge H, Kim E, Cho H, Micol JB, Chung YR, et al. Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. Nat Med. 2016;22(6):672\u20138.","journal-title":"Nat Med"},{"key":"2242_CR77","unstructured":"Silvia Buonamici AY, Thomas M, Seiler M, Chan B, Caleb B, Darman R, Fekkes P, Karr C, Keaney G, Klimek V, Kunii K, Lee L, Chun-Wei Lee S, Liu X, Meeske C, Mizui Y, Padron E, Park E, Pazolli E, Prajapati S, Taylor J, Wang J, Warmuth M, Yu L, Zhu P, Abdel-Wahab O, Smith P. H3B-8800, an orally bioavailable modulator of the SF3b complex, shows efficacy in spliceosome-mutant myeloid malignancies. In: 58th ASH annual meeting and exposition abstract."},{"issue":"1","key":"2242_CR78","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1182\/blood-2014-07-591461","volume":"125","author":"S Groschel","year":"2015","unstructured":"Groschel S, Sanders MA, Hoogenboezem R, Zeilemaker A, Havermans M, Erpelinck C, et al. Mutational spectrum of myeloid malignancies with inv(3)\/t(3;3) reveals a predominant involvement of RAS\/RTK signaling pathways. Blood. 2015;125(1):133\u20139.","journal-title":"Blood"},{"issue":"2","key":"2242_CR79","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","volume":"28","author":"T Haferlach","year":"2014","unstructured":"Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28(2):241\u20137.","journal-title":"Leukemia"},{"issue":"5","key":"2242_CR80","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2016-01-693879","volume":"128","author":"KH Metzeler","year":"2016","unstructured":"Metzeler KH, Herold T, Rothenberg-Thurley M, Amler S, Sauerland MC, Gorlich D, et al. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. Blood. 2016;128(5):686\u201398.","journal-title":"Blood"},{"key":"2242_CR81","unstructured":"Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122(22):3616\u201327 (Quiz 99)."}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-017-2242-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-017-2242-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-017-2242-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T18:13:50Z","timestamp":1602008030000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-017-2242-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,2]]},"references-count":81,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["2242"],"URL":"https:\/\/doi.org\/10.1007\/s12185-017-2242-0","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,2]]}}}